EFFECT OF WITHANIA SOMNIFERA (ASHWAGANDHA) ON LIPID PROFILE PARAMETERS IN MDD (MAJOR DEPRESSIVE DISORDER) PATIENTS WHO ARE ON SERTRALINE.
Main Article Content
Keywords
Antidepressants, Ashwagandha, Depression, Lipid profile, MDD, Sertraline.
Abstract
Aim and Objectives: Aim: To study the effect of administration of sertraline alone and sertraline with ashwagandha on Lipid Profile Parameters in patients with MDD (Major Depressive Disorder). Objectives:1. To estimate the effect of sertraline on Lipid Profile Parameters in patients with MDD. 2. To estimate the effect of co-administration of ashwagandha with sertraline on Lipid Profile Parameters. 3. To compare Lipid Profile Parameters of both the groups before and after treatment. Material and Methods: This was an open labelled, randomized, comparative, prospective study involving 80 newly diagnosed patients with MDD according to inclusion and exclusion criteria. After enrolling, participants were randomly allocated in either of the groups. One who are taking routine treatment with sertraline (Sertraline Group) and another who are given ashwagandha with their routine treatment with sertraline (Sertraline + Ashwagandha Group). All Lipid Profile Parameters were investigated before starting the treatment and reinvestigated after a period of 3 months of drug treatment in both the groups. Results: In sertraline group, values of Total Cholesterol, Triglyceride, VLDL and LDL were significantly increased. Whereas there was no significant difference in value of HDL. In sertraline + ashwagandha group values of Total Cholesterol and LDL were significantly decreased. Whereas there was no significant difference in values of Triglyceride, VLDL and HDL levels before and after three months of treatment. Conclusion: we can conclude prolonged sertraline treatment can derange the lipid profile parameters (Total cholesterol, Triglyceride, VLDL and LDL) and concurrent administration of Ashwagandha can prevent this derangement of lipid profile parameters. However, Sertraline or sertraline + ashwagandha does not have any effect on HDL levels.
References
2. Sagar R, Dandona R, Gururaj G, Dhaliwal RS, Singh A, Ferrari A, Dua T, Ganguli A, Varghese M, Chakma JK, Kumar GA. The burden of mental disorders across the states of India: the Global Burden of Disease Study 1990–2017. The Lancet Psychiatry. 2020 Feb 1;7(2):148-61.
3. Brigitta B. Pathophysiology of depression and mechanisms of treatment. Dialogues in clinical neuroscience. 2022 Apr 1.
4. DeLucia V, Kelsberg G, Safranek S. Which SSRIs most effectively treat depression in adolescents? J Fam Pract. 2016 Sep;65(9):632-4.
5. Gandotra K, Jaskiw G, Fuller M, Vaidya P, Chiang A, Konicki E, Strohl KP. Sertraline as an adjunctive treatment for insomnia comorbid with other mental health disorders. Journal of Affective Disorders Reports. 2022 Dec 1;10:100389.
6. Murdoch D, McTavish D. Sertraline. Drugs. 1992 Oct;44(4):604-24.
7. Colotto M, Vinci F, Raimo O, Castello A, Carnovale A, Paciaroni A, Coletta P. Effect of treatment with selective serotonin reuptake inhibitors on lipid profile: state of the art. La Clinica Terapeutica. 2012 Jan 1;163(1):e41-5.
8. Kesim M, Tiryaki A, Kadioglu M, Muci E, Kalyoncu NI, Yaris E. The effects of sertraline on blood lipids, glucose, insulin and HBA1C levels: a prospective clinical trial on depressive patients. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences. 2011 Dec;16(12):1525.
9. Pala B. Withania Somnifera (Ashwagandha): A Source Of Therapeutic Agents Nikhil Teli, Trupti Bagwe 2, Ashwathi Kandampully And.
10. Umadevi M, Rajeswari R, Rahale CS, Selvavenkadesh S, Pushpa R, Kumar KS, Bhowmik D. Traditional and medicinal uses of Withania somnifera. The pharma innovation. 2012 Nov 1;1(9, Part A):102.
11. Andallu B, Radhika B. Hypoglycemic, diuretic and hypocholesterolemic effect of winter cherry (Withania somnifera, Dunal) root.
12. Maity T, Adhikari A, Bhattacharya K, Biswas S, Debnath PK, Maharana CS. A study on evalution of antidepressant effect of imipramine adjunct with Aswagandha and Bramhi. Nepal Med Coll J. 2011 Dec 1;13(4):250-3.
13. American Psychiatric Association. Practice Guideline For The Treatment of Patients With Major Depressive Disorder, Third Edition. November 2010.
14. Fjukstad KK, Engum A, Lydersen S, Dieset I, Steen NE, Andreassen OA, Spigset O. Metabolic abnormalities related to treatment with selective serotonin reuptake inhibitors in patients with schizophrenia or bipolar disorder. Journal of clinical psychopharmacology. 2016 Dec;36(6):615.
15. Wei F, Crain AL, Whitebird RR, Godlevsky OV, O'connor PJ. Effects of paroxetine and sertraline on low-density lipoprotein cholesterol: an observational cohort study. CNS Drugs 2009;23(10):857-65.
16. Herran A, Ramirez ML, Carrera M, Garcia-Unzueta MT, Sierra-Biddle D, Rodriguez-Cabo B, et al. Panic disorder, treatment with selective serotonin reuptake inhibitors, and cholesterol levels. J Clin Psychopharmacol 2006; 26(5): 538-40.
17. Beyazyüz M, Albayrak Y, Eğilmez OB, Albayrak N, Beyazyüz E. Relationship between SSRIs and metabolic syndrome abnormalities in patients with generalized anxiety disorder: a prospective study. Psychiatry investigation. 2013 Jun;10(2):148.
18. Raut AA, Rege NN, Tadvi FM, Solanki PV, Kene KR, Shirolkar SG, Pandey SN, Vaidya RA, Vaidya AB. Exploratory study to evaluate tolerability, safety, and activity of Ashwagandha (Withania somnifera) in healthy volunteers. Journal of Ayurveda and integrative medicine. 2012 Jul;3(3):111.
19. Visavadiya NP, Narasimhacharya AV. Hypocholesteremic and antioxidant effects of Withania somnifera (Dunal) in hypercholesteremic rats. Phytomedicine. 2007 Feb 19;14(2-3):136-42.
20. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European heart journal. 2017 Aug 21;38(32):2459-72.
21. Cooney MT, Dudina A, De Bacquer D, Wilhelmsen L, Sans S, Menotti A, De Backer G, Jousilahti P, Keil U, Thomsen T, Whincup P. HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. Atherosclerosis. 2009 Oct 1;206(2):611-6.
22. Eker ÖO, Özsoy S, Baki EK, Doğan H. Metabolic effects of antidepressant treatment. Archives of Neuropsychiatry. 2017 Mar;54(1):49.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Keyurkumar M Vaghasiya
Assistant Professor, Department of Pharmacology, Kiran Medical College, Surat, Gujarat, India.
Dr. Vipul Navadiya
Assistant Professor, Department of Pharmacology, Kiran Medical College, Surat, Gujarat, India.
Dr. Haiya Sheth
Associate Professor, Department of Pharmacology, Kiran Medical College, Surat, Gujarat, India.
